TELA Bio officer reports RSU grant, tax dispositions

TELA Bio, Inc. Chief Accounting Officer Megan Smeykal reported multiple equity transactions involving the company’s common stock.

Rhea-AI Filing Summary

TELA Bio, Inc. Chief Accounting Officer Megan Smeykal reported multiple equity transactions involving the company’s common stock. On February 18, 2026, she acquired 32,850 shares through a grant of restricted stock units (RSUs) at a stated price of $0.0000 per share. According to the footnotes, these RSUs vest in four equal annual installments beginning on February 18, 2027, contingent on her continued service.

On February 19, 21, and 23, 2026, shares of common stock were disposed of in three separate transactions coded “F,” each described as a tax-withholding disposition to satisfy withholding taxes upon RSU vesting. After the latest transaction, her direct holdings stood at 66,873 shares of common stock.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Smeykal Megan

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	423	$0.766	$324.02
Exercise Price or Tax Liability	Common Stock	1,590	$0.7174	$1K
Exercise Price or Tax Liability	Common Stock	795	$0.795	$632.03
Grant/Award	Common Stock	32,850	$0.00	$0.00

Holdings After Transaction: Common Stock — 66,873 shares (Direct)

Footnotes (2)

1. F1. These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continuous service through the applicable vesting dates.
2. F2. Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TELA (TELA) report for Megan Smeykal?

TELA Bio reported that Chief Accounting Officer Megan Smeykal received a grant of 32,850 restricted stock units and had three tax-withholding share dispositions in February 2026. These transactions involved the company’s common stock and adjusted her directly held share balance.

How many TELA (TELA) shares did Megan Smeykal acquire in the latest grant?

Megan Smeykal acquired 32,850 shares through a restricted stock unit grant on February 18, 2026. The grant is recorded at a price of $0.0000 per share and represents an equity award rather than an open-market purchase.

When do Megan Smeykal’s TELA (TELA) RSUs begin vesting?

Her restricted stock units begin vesting on February 18, 2027. The RSUs will vest in four equal annual installments, and each installment is conditioned on her continuous service with TELA Bio through the applicable vesting dates.

Why did TELA (TELA) report tax-withholding dispositions for Megan Smeykal?

The filing states that shares were withheld by TELA Bio to satisfy applicable withholding taxes upon vesting of restricted stock units. These dispositions are coded as tax-withholding transactions rather than open-market sales or discretionary share sales.

How many TELA (TELA) shares does Megan Smeykal hold after these transactions?

Following the most recent reported transaction on February 23, 2026, Megan Smeykal directly held 66,873 shares of TELA Bio common stock. This figure reflects the impact of both the RSU grant and the related tax-withholding share dispositions.

What do the F-coded transactions mean in the TELA (TELA) Form 4?

The F-coded transactions are described as payment of tax liability by delivering securities. In this case, they represent shares withheld by TELA Bio to cover withholding taxes when restricted stock units vested, not open-market buying or selling activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 08:00 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smeykal Megan

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		A		32,850(1)	A	$0	69,681	D
Common Stock	02/19/2026		F		795(2)	D	$0.795	68,886	D
Common Stock	02/21/2026		F		1,590(2)	D	$0.7174	67,296	D
Common Stock	02/23/2026		F		423(2)	D	$0.766	66,873	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continuous service through the applicable vesting dates.

2. Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

	/s/ Megan Smeykal	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.